Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AWH Stock Forecast 2026-2027
$0.16
Current Price
$2.89M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AWH Price Targets
+3,256.7%
To High Target of $5.50
+3,256.7%
To Median Target of $5.50
+3,256.7%
To Low Target of $5.50
AWH Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-68.0%
1 Year Change
0.0%
Year-to-Date Change
-91.3%
From 52W High of $1.89
+715.2%
From 52W Low of $0.02
📊 TOP ANALYST CALLS
Did AWH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aspira Women's Health is one of their latest high-conviction picks.
Latest AWH Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, AWH has a bullish consensus with a median price target of $5.50 (ranging from $5.50 to $5.50). The overall analyst rating is N/A (N/A/10). Currently trading at $0.16, the median forecast implies a 3,256.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ben Haynor at Alliance Global Partners, projecting a 3,256.7% upside. Conversely, the most conservative target is provided by Ben Haynor at Alliance Global Partners, suggesting a 3,256.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AWH Analyst Ratings
1
Buy
0
Hold
0
Sell
AWH Price Target Range
Low
$5.50
Average
$5.50
High
$5.50
Current: $0.16
Latest AWH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AWH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 14, 2024 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $5.50 |
| Apr 10, 2024 | Cantor Fitzgerald | Neutral | Reiterates | $N/A | |
| Apr 1, 2024 | Cantor Fitzgerald | Neutral | Maintains | $N/A | |
| Sep 26, 2023 | Cantor Fitzgerald | Neutral | Reiterates | $N/A | |
| Aug 22, 2023 | Alliance Global Partners | Buy | Initiates | $N/A | |
| May 17, 2023 | Cantor Fitzgerald | Neutral | Maintains | $N/A |
Aspira Women's Health Inc. (AWH) Competitors
The following stocks are similar to Aspira Women's Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aspira Women's Health Inc. (AWH) Financial Data
Valuation Metrics
Market Cap
$2.89M
Enterprise Value
$4.05M
P/E Ratio
N/A
PEG Ratio
-0.1x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
+10.3%
Gross Margin
+68.5%
Operating Margin
-146.1%
Net Margin
-142.6%
EPS Growth
+5.9%
Financial Health
Cash/Price Ratio
+36.0%
Current Ratio
0.8x
Debt/Equity
-56.3x
ROE
+510.9%
ROA
-173.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aspira Women's Health Inc. (AWH) Business Model
About Aspira Women's Health Inc.
What They Do
Develops AI-powered diagnostic tests for gynecologic diseases.
Business Model
The company generates revenue by commercializing noninvasive diagnostic tests aimed at identifying gynecologic conditions, particularly ovarian cancer and endometriosis. It provides these tests through a national sales force, partnerships, and a specialized laboratory, serving healthcare providers and laboratories.
Additional Information
Aspira Women's Health has developed several key products, including Ova1Plus and Overa, and is involved in ongoing research collaborations with prestigious institutions like Harvard. The company has rebranded from Vermillion, Inc. and has strategic alliances with organizations such as Quest Diagnostics to enhance its market presence.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
66
CEO
Country
United States
IPO Year
2001
Website
aspirawh.comAspira Women's Health Inc. (AWH) Latest News & Analysis
Latest News
Quick Summary
Aspira Women's Health Inc. reported flat total product revenues of $2.3 million for Q3 2025, matching the same period in 2024, as per their operational results announcement.
Why It Matters
Flat revenue growth at Aspira indicates potential stagnation in market demand or competitive challenges, which could raise concerns about future profitability and investment viability.
Source: Accesswire
Market Sentiment:
Neutral
Aspira Women's Health Wins Laboratory Service Contract with University of Texas Medical Branch at Galveston
2 months ago
Quick Summary
Aspira Women's Health Inc. signed a 12-month laboratory services agreement with UTMB Galveston, aimed at expanding its market reach and improving access to its gynecologic diagnostics.
Why It Matters
Aspira's new agreement with UTMB Galveston enhances market access and scalability, potentially boosting revenue and patient reach, which could positively influence stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Aspira Women's Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise
4 months ago
Quick Summary
Aspira Women's Health Inc. raised $3.06 million through a private placement, issuing $2.95 million in common stock and warrants to existing and new investors, including Board members.
Why It Matters
Aspira Women's Health raised $3.06 million through a PIPE deal, enhancing liquidity and signaling investor confidence, which can positively impact stock performance and market perception.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Aspira Women's Health Inc. appointed Brian Hungerford as Chief Financial Officer on September 2, 2025. He brings over 20 years of experience in accounting, capital markets, and biotechnology.
Why It Matters
The appointment of a seasoned CFO with extensive experience in accounting and capital markets can enhance financial governance, potentially increasing investor confidence and company stability.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Aspira Women's Health Inc. (OTCQB:AWHL) reported its operational results for Q2 and H1 2025, highlighting early progress under new leadership in women's health diagnostics.
Why It Matters
Aspira's financial results and leadership changes signal potential growth and innovation in women's health diagnostics, impacting investor confidence and company valuation.
Source: Accesswire
Market Sentiment:
Neutral
Aspira Women's Health Announces Appointment of Jane Pine Wood to the Board of Directors
6 months ago
Quick Summary
Aspira Women's Health Inc. appointed Jane Pine Wood to its Board of Directors on July 11, 2025, enhancing its leadership in gynecologic disease diagnostics.
Why It Matters
The appointment of Jane Pine Wood to Aspira's Board could enhance governance and strategic direction, potentially driving growth and improving investor confidence in the company's future.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About AWH Stock
What is Aspira Women's Health Inc.'s (AWH) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Aspira Women's Health Inc. (AWH) has a median price target of $5.50. The highest price target is $5.50 and the lowest is $5.50.
Is AWH stock a good investment in 2026?
According to current analyst ratings, AWH has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AWH stock?
Wall Street analysts predict AWH stock could reach $5.50 in the next 12 months. This represents a 3,256.7% increase from the current price of $0.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aspira Women's Health Inc.'s business model?
The company generates revenue by commercializing noninvasive diagnostic tests aimed at identifying gynecologic conditions, particularly ovarian cancer and endometriosis. It provides these tests through a national sales force, partnerships, and a specialized laboratory, serving healthcare providers and laboratories.
What is the highest forecasted price for AWH Aspira Women's Health Inc.?
The highest price target for AWH is $5.50 from Ben Haynor at Alliance Global Partners, which represents a 3,256.7% increase from the current price of $0.16.
What is the lowest forecasted price for AWH Aspira Women's Health Inc.?
The lowest price target for AWH is $5.50 from Ben Haynor at Alliance Global Partners, which represents a 3,256.7% increase from the current price of $0.16.
What is the overall AWH consensus from analysts for Aspira Women's Health Inc.?
The overall analyst consensus for AWH is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.50.
How accurate are AWH stock price projections?
Stock price projections, including those for Aspira Women's Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 1:37 AM UTC